Dacarbazine
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-DACARBAZINE |
|---|---|
| Type | Drug |
| Aliases | DTIC-DomeДакарбазин |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-CHL |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Imidazole-carboxamide alkylating agent |
|---|---|
| Mechanism | Activated to MTIC (methyl-triazenyl-imidazole carboxamide) which methylates DNA → strand breaks + apoptosis. |
| Typical dosing | ABVD: 375 mg/m² IV days 1+15 of 28-day cycle |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
ABVD (Hodgkin) component. Highly emetogenic — triple-combo antiemetic prophylaxis. Avoid sun exposure during therapy + 1 week after.
Used By
Regimens
REG-A-AVD- A+AVD (Brentuximab vedotin + Adriamycin + Vinblastine + Dacarbazine), 6 cyclesREG-ABVD- ABVD (Adriamycin + Bleomycin + Vinblastine + Dacarbazine), 2-6 cyclesREG-NIVO-AVD- N+AVD (Nivolumab + Adriamycin + Vinblastine + Dacarbazine), 6 cycles — emerging 1L standa...